Inactive Provider
This provider's NPI has been deactivated on 04/09/2026. The information on this page is historical and may no longer be current.
Total Payments
$407,614
2024 Payments
$2,201
Companies
62
Transactions
1,976
Medicare Patients
1,343
Medicare Billing
$569,386
Payment Breakdown by Category
Other$320,002 (78.5%)
Consulting$35,411 (8.7%)
Food & Beverage$29,207 (7.2%)
Travel$13,782 (3.4%)
Research$8,628 (2.1%)
Education$585.58 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $307,864 | 184 | 75.5% |
| Consulting Fee | $35,411 | 32 | 8.7% |
| Food and Beverage | $29,207 | 1,578 | 7.2% |
| Travel and Lodging | $13,782 | 150 | 3.4% |
| Honoraria | $12,138 | 6 | 3.0% |
| Unspecified | $8,628 | 6 | 2.1% |
| Education | $585.58 | 20 | 0.1% |
Payments by Type
General
$398,987
1,970 transactions
Research
$8,628
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $60,747 | 251 | $0 (2022) |
| Amgen Inc. | $52,439 | 120 | $0 (2024) |
| Merck Sharp & Dohme LLC | $44,548 | 77 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $41,144 | 191 | $0 (2024) |
| ABBVIE INC. | $39,948 | 281 | $0 (2024) |
| Lilly USA, LLC | $26,944 | 91 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $19,483 | 30 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $18,792 | 53 | $0 (2021) |
| Lundbeck LLC | $18,615 | 138 | $0 (2024) |
| EISAI INC. | $18,375 | 32 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,201 | 113 | ABBVIE INC. ($1,015) |
| 2023 | $23,435 | 215 | IDORSIA PHARMACEUTICALS US INC ($14,571) |
| 2022 | $36,759 | 294 | ABBVIE INC. ($11,182) |
| 2021 | $75,209 | 302 | AbbVie Inc. ($23,384) |
| 2020 | $84,127 | 319 | Allergan, Inc. ($48,697) |
| 2019 | $42,976 | 254 | Teva Pharmaceuticals USA, Inc. ($14,683) |
| 2018 | $82,529 | 288 | Amgen Inc. ($36,106) |
| 2017 | $60,379 | 191 | Merck Sharp & Dohme Corporation ($44,323) |
All Payment Transactions
1,976 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: Neuroscience | ||||||
| 11/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $2.82 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $1.54 | General |
| Category: Neurology | ||||||
| 11/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: PAIN | ||||||
| 11/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $27.74 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.55 | General |
| Category: PSYCHIATRY | ||||||
| 11/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.96 | General |
| Category: PAIN | ||||||
| 10/11/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: Musculoskeletal | ||||||
| 10/09/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $5.64 | General |
| Category: Neurology | ||||||
| 10/09/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Education | In-kind items and services | $1.54 | General |
| Category: Neurology | ||||||
| 10/08/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/08/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/02/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $27.10 | General |
| Category: PAIN | ||||||
| 10/02/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $18.98 | General |
| Category: NEUROLOGY | ||||||
| 09/25/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/24/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: PSYCHIATRY | ||||||
| 09/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $6.31 | General |
| Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $4,773 | 2 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC CLUSTER HEADACHE | Eli Lilly and Company | $1,714 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $620.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $620.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 361 | 18,559 | $243,952 | $165,462 |
| 2022 | 4 | 345 | 17,497 | $217,679 | $154,079 |
| 2021 | 4 | 315 | 14,542 | $186,108 | $134,847 |
| 2020 | 4 | 322 | 12,830 | $171,045 | $114,998 |
Total Patients
1,343
Total Services
63,428
Medicare Billing
$569,386
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 54 | 17,663 | $113,534 | $81,280 | 71.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 229 | 726 | $98,491 | $63,067 | 64.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 56 | 148 | $26,692 | $17,794 | 66.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $5,235 | $3,321 | 63.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 53 | 16,669 | $103,222 | $75,454 | 73.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 215 | 669 | $84,436 | $57,252 | 67.8% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 52 | 134 | $24,309 | $17,204 | 70.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $5,712 | $4,169 | 73.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 46 | 13,808 | $85,073 | $65,737 | 77.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 207 | 594 | $74,325 | $50,664 | 68.2% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 48 | 126 | $23,324 | $16,294 | 69.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $3,386 | $2,152 | 63.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 48 | 12,120 | $73,611 | $54,348 | 73.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 205 | 574 | $71,278 | $43,266 | 60.7% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 49 | 116 | $21,314 | $14,718 | 69.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $4,842 | $2,666 | 55.1% |
About Dr. Lawrence Robbins, M.D
Dr. Lawrence Robbins, M.D is a Brain Injury Medicine healthcare provider based in Riverwoods, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1770630212.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence Robbins, M.D has received a total of $407,614 in payments from pharmaceutical and medical device companies, with $2,201 received in 2024. These payments were reported across 1,976 transactions from 62 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($307,864).
As a Medicare-enrolled provider, Robbins has provided services to 1,343 Medicare beneficiaries, totaling 63,428 services with total Medicare billing of $569,386. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Brain Injury Medicine
- Other Specialties Neurology, Neurology
- Location Riverwoods, IL
- Active Since 01/05/2007
- Last Updated 10/27/2020
- Taxonomy Code 2081P0301X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770630212
Products in Payments
- UBRELVY (Drug) $83,105
- BELSOMRA (Drug) $44,548
- Aimovig (Biological) $43,008
- NURTEC ODT (Drug) $24,159
- QUVIVIQ (Drug) $19,483
- AJOVY (Biological) $18,379
- Dayvigo (Drug) $18,357
- VYEPTI (Biological) $17,900
- AJOVY (Drug) $17,690
- EMGALITY (Drug) $16,642
- TROKENDI XR (Drug) $14,968
- Zembrace (Drug) $10,646
- Trudhesa (Drug) $8,086
- QULIPTA (Drug) $6,303
- BOTOX - MIGRAINE (Drug) $5,226
- ONZETRA Xsail (Drug) $4,209
- ELYXYB - CELECOXIB (Drug) $3,017
- VRAYLAR (Drug) $1,843
- REXULTI (Drug) $1,554
- BOTOX (Biological) $1,130
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.